Los Angeles, CA -- (SBWire) -- 04/10/2019 --Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%, and the proportion is increasing trend from 2013 to 2018.

Biosimilar Monoclonal Antibodies is widely used for Oncology, Autoimmune Disease and Others. The most proportion of Biosimilar Monoclonal Antibodies is sales in Autoimmune Disease, and the consumption proportion is about 85.6% in 2017.

Europe is the largest consumption place, with a revenue market share nearly 51.4% in 2017. Following Europe, North America is the second largest consumption place with the revenue market share of 26.2%, China is also an important sales region for the Biosimilar Monoclonal Antibodies.

The global Biosimilar Monoclonal Antibodies market was 1510 million US$ in 2018 and is expected to 15200 million US$ by the end of 2025, growing at a CAGR of 33.5% between 2019 and 2025.

Get PDF template of this report: https://www.qyresearch.com/sample-form/form/1076672/global-biosimilar-monoclonal-antibodies-market

This report studies the Biosimilar Monoclonal Antibodies market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Biosimilar Monoclonal Antibodies in these regions, from 2014 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

Celltrion

Pfizer (Hospira)

3SBIO

Novartis (Sandoz)

Dr Reddy's

Celgen Biopharma

Cadila Healthcare

Hisun Pharma

Torrent Pharmaceuticals

By the product type, the market is primarily split into

Infliximab

Rituximab

Trastuzumab

Adalimumab

Other

By the end users/application, this report covers the following segments

Oncology

Autoimmune Disease

Other

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Rest of Asia-Pacific

Europe

Germany

France

UK

Italy

Spain

Russia

Rest of Europe

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

Rest of Middle East & Africa

Get Full Report Now at USD 2,900 @ https://www.qyresearch.com/settlement/pre/da9d91c354cf4f4b6f97089c2d710e06,0,1,Global%20Biosimilar%20Monoclonal%20Antibodies%20Market%20Report,%20History%20and%20Forecast%202014-2025,%20Breakdown%20Data%20by%20Manufacturers,%20Key%20Regions,%20Types%20and%20Application

About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.